{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:05:24Z","timestamp":1773288324236,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of the Epitomee capsule on quality of life (QOL) and its association with weight loss in adults with overweight and obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed the RESET double-blind, placebo-controlled results, focusing on predefined QOL endpoints and post hoc analyses. A total of 279 participants with a BMI of 27\u201340\u2009kg\/m\u00b2 were treated for 24 weeks with Epitomee or placebo, along with lifestyle intervention. Statistical analyses examined changes in IWQOL-Lite-CT scores, their relationship with weight loss, and subgroup differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to the placebo group, the Epitomee group consistently showed improved outcomes in total IWQOL-Lite-CT score and Physical Function sub-score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), as well as numerically higher improvements in the Physical and Psychosocial sub-scores, although these did not reach statistical significance. Both treatment groups showed a significant improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) from baseline in the IWQOL-Lite-CT total score, as well as in Physical, Physical Function, and Psychosocial sub-scores over the 24-week period. A stronger correlation between weight loss and QOL improvements was observed with Epitomee vs. placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Epitomee capsule, with lifestyle intervention, is associated with IWQOL-Lite-CT improvement, highlighting its potential as an effective non-pharmaceutical adjunct to lifestyle intervention for enhancing health outcomes in individuals with overweight and obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-025-01910-6","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:20:59Z","timestamp":1758039659000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-3705","authenticated-orcid":false,"given":"Robert F.","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-6795","authenticated-orcid":false,"given":"Jamy D.","family":"Ard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-4609","authenticated-orcid":false,"given":"Thomas A.","family":"Wadden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-6111","authenticated-orcid":false,"given":"Frank L.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-9368","authenticated-orcid":false,"given":"John M.","family":"Jakicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly R.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Kenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liora Cohen","family":"Asaraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"1910_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s11136-022-03191-2","volume":"32","author":"J-L Poon","year":"2023","unstructured":"Poon J-L, Marshall C, Johnson C, Pegram HC, Hunter M, Kan H, et al. A qualitative study to examine meaningful change in physical function associated with weight-loss. Qual Life Res. 2023;32:1329\u201340.","journal-title":"Qual Life Res"},{"key":"1910_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JPH, World Obesity F. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18:715\u201323.","journal-title":"Obes Rev"},{"key":"1910_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1037\/amp0000550","volume":"75","author":"DB Sarwer","year":"2020","unstructured":"Sarwer DB, Heinberg LJ. A review of the psychosocial aspects of clinically severe obesity and bariatric surgery. Am Psychol. 2020;75:252\u201364.","journal-title":"Am Psychol"},{"key":"1910_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","volume":"6","author":"K Bhaskaran","year":"2018","unstructured":"Bhaskaran K, dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK. Lancet Diab Endocrinol. 2018;6:944\u201353.","journal-title":"Lancet Diab Endocrinol"},{"key":"1910_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"The GBD 2015 Obesity Collaborators.","year":"2017","unstructured":"The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13\u201327.","journal-title":"N Engl J Med"},{"key":"1910_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0899-9007(00)00404-4","volume":"16","author":"RF Kushner","year":"2000","unstructured":"Kushner RF, Foster GD. Obesity and quality of life. Nutrition. 2000;16:947\u201352.","journal-title":"Nutrition"},{"key":"1910_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-resource-022823-033521","volume":"15","author":"S Bansal","year":"2023","unstructured":"Bansal S, Jin Y. Heterogeneous effects of obesity on life expectancy: a global perspective. Annu Rev Resour Econ. 2023;15:433\u2013554.","journal-title":"Annu Rev Resour Econ"},{"key":"1910_CR8","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1038\/ijo.2013.93","volume":"37","author":"DB Sarwer","year":"2013","unstructured":"Sarwer DB, Moore RH, Diewald LK, Chittams J, Berkowitz RI, Vetter M, et al. The impact of a primary care-based weight loss intervention on the quality of life. Int J Obes. 2013;37:S25\u2013S30.","journal-title":"Int J Obes"},{"key":"1910_CR9","unstructured":"Center for Drug Evaluation and Research. Patient-reported outcome measures: use in medical product development to support labeling claims, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (2009, accessed 21 January 2025)."},{"key":"1910_CR10","unstructured":"Center for Drug Evaluation and Research. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome (2022, accessed 21 January 2025)."},{"key":"1910_CR11","doi-asserted-by":"publisher","first-page":"12310","DOI":"10.1111\/cob.12310","volume":"9","author":"RL Kolotkin","year":"2019","unstructured":"Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, et al. Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version. Clin Obes. 2019;9:12310.","journal-title":"Clin Obes"},{"key":"1910_CR12","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.1111\/cob.12477","volume":"11","author":"RL Kolotkin","year":"2021","unstructured":"Kolotkin RL, Williams VSL, Von Huth Smith L, Meincke HH, Qin S, Williams N, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life\u2013Lite Clinical Trials Version (IWQOL-Lite-CT). Clin Obes. 2021;11:12477.","journal-title":"Clin Obes"},{"key":"1910_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/osp4.343","volume":"5","author":"H Shirin","year":"2019","unstructured":"Shirin H, Richter V, Matalon S, Abramowich D, Maliar A, Shachar E, et al. Safety, tolerability and efficacy of a novel self-use biodegradable device for management of obesity. Obes Sci Pract. 2019;5:376\u201382.","journal-title":"Obes Sci Pract"},{"key":"1910_CR14","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.obpill.2023.100094","volume":"8","author":"H Shirin","year":"2023","unstructured":"Shirin H, Neeland IJ, Ryan DH, de Luis D, Lecube A, Magos Z, et al. Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size. Obes Pillars. 2023;8:100094.","journal-title":"Obes Pillars"},{"key":"1910_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/oby.24240","volume":"33","author":"JD Ard","year":"2025","unstructured":"Ard JD, Ryan DH, O'Neil PM, Kushner RF, Wyatt HR, Bays HE, et al. Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. Obesity. 2025;33:500\u201311.","journal-title":"Obesity"},{"key":"1910_CR16","doi-asserted-by":"crossref","unstructured":"Jakicic JM, Ryan DH, Ard HD, O'Neil PM, Kushner RF, et al. Association of the early response to an oral shape-shifting superabsorbent hydrogel capsule with weight loss. Clin Obes. 2025;0:e70037.","DOI":"10.1111\/cob.70037"},{"key":"1910_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","volume":"27","author":"KA Gudzune","year":"2025","unstructured":"Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diab Obes Metab. 2025;27:539\u201350.","journal-title":"Diab Obes Metab"},{"key":"1910_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"1910_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cob.12146","volume":"6","author":"RL Kolotkin","year":"2016","unstructured":"Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes. 2016;6:233\u201342.","journal-title":"Clin Obes"},{"key":"1910_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/oby.2001.73","volume":"9","author":"RL Kolotkin","year":"2001","unstructured":"Kolotkin RL, Crosby RD, Williams GR, Hartley GG, Nicol S. The relationship between health-related quality of life and weight loss. Obes Res. 2001;9:564\u201371.","journal-title":"Obes Res"},{"key":"1910_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-12009-8","volume":"21","author":"J Stephenson","year":"2021","unstructured":"Stephenson J, Smith CM, Kearns B, Haywood A, Bissell P. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21:1990.","journal-title":"BMC Public Health"},{"key":"1910_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.22187","volume":"26","author":"RL Pearl","year":"2018","unstructured":"Pearl RL, Wadden TA, Tronieri JS, Berkowitz RI, Chao AM, Alamuddin N, et al. Short- and long-term changes in health-related quality of life with weight loss: results from a randomized controlled trial. Obesity. 2018;26:985\u201391.","journal-title":"Obesity"},{"key":"1910_CR23","doi-asserted-by":"publisher","first-page":"13553","DOI":"10.1111\/obr.13553","volume":"24","author":"R Jobanputra","year":"2023","unstructured":"Jobanputra R, Sargeant JA, Almaqhawi A, Ahmad E, Arsenyadis F, Webb DR, et al. The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2023;24:13553.","journal-title":"Obes Rev"},{"key":"1910_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/cob.12203","volume":"7","author":"RL Kolotkin","year":"2017","unstructured":"Kolotkin RL, Andersen JR. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes. 2017;7:273\u201389.","journal-title":"Clin Obes"},{"key":"1910_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11482-019-09776-3","volume":"16","author":"K Zawisza","year":"2021","unstructured":"Zawisza K, Tobiasz-Adamczyk B, Galas A, Jab\u0142o\u0144ska K, Grodzicki T. Changes in body mass index and quality of life\u2014population-based follow-up study COURAGE and COURAGE-POLFUS, Poland. Appl Res Qual Life. 2021;16:501\u201326.","journal-title":"Appl Res Qual Life"},{"key":"1910_CR26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/ijerph18041785","volume":"18","author":"L Dainelli","year":"2021","unstructured":"Dainelli L, Luo DR, Cohen SS, Marczewska A, Ard JD, Coburn SL, et al. Health-related quality of life in weight loss interventions: results from the OPTIWIN trial. IJERPH. 2021;18:1785.","journal-title":"IJERPH"},{"key":"1910_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/00325481.2022.2150006","volume":"134","author":"PM O\u2019Neil","year":"2022","unstructured":"O\u2019Neil PM, Rubino DM. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgrad Med. 2022;134:28\u201336.","journal-title":"Postgrad Med"},{"key":"1910_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diab Care. 2011;34:1481\u20136.","journal-title":"Diab Care"},{"key":"1910_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1\u2013203.","journal-title":"Endocr Pract"},{"key":"1910_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187\u201394.","journal-title":"Curr Obes Rep"}],"updated-by":[{"DOI":"10.1038\/s41366-025-01962-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000}}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01910-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:14:18Z","timestamp":1769703258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01910-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1038\/s41366-025-01910-6","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to misspelling of the last author. The name should read Donna H. Ryan instead of Ryan H. Ryan.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41366-025-01962-8","URL":"https:\/\/doi.org\/10.1038\/s41366-025-01962-8","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RFK has received grant support from Epitomee Medical Ltd, received consulting fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Structure, Altimmune, Regeneron, Currax, and Weight Watchers, and holds a voluntary committee membership position at the American Diabetes Association. JDA has received grant support from Nestle Healthcare Nutrition, Eli Lilly, Boehringer Ingelheim, Epitomee, Inc., UnitedHealth Group R&D, KVKTech, and WW, consulting fees from Nestle Healthcare Nutrition, Eli Lilly, Optum Labs R&D, Novo Nordisk, Intuitive, Regeneron, Brightseed, Level2, WW, Amgen, and Boehringer Ingelheim, receipt of equipment, materials, drugs, medical writing, gifts or other services from KVKTech, WW, and Nestle Healthcare Nutrition, and serves as President of The Obesity Society and an Executive Board Member for the American Society for Nutrition Foundation. TAW has received grant support, on behalf of the Trustees of the University of Pennsylvania, from Eli Lilly, Epitomee Medical, and Novo Nordisk, and has served on scientific advisory boards for Eli Lilly, Novo Nordisk, and WW. PMO has received grant support from Epitomee Medical Ltd, Novo Nordisk and Eli Lilly, consulting fees from Novo Nordisk, participated on an advisory board for Novo Nordisk, and has an unpaid leadership or fiduciary role for the Diabetes Initiative of South Carolina. HEB has received grant support from 89Bio, Alon Medtech\/Epitomee, Altimmune, Amgen, Bioage, Boehringer Ingelheim, Carmot, Chorus\/Bioage, Eli Lilly, Evidera, Kallyope, Novartis, NovoNordisk, Pfizer, Regeneron, Satsuma, Selecta, Shionogi, Skye\/Birdrock, Veru, Viking, and Vivus, consulting fees from 89Bio, Altimmune, Amgen, Boehringer Ingelheim, Kiniksa, HighTide, Lilly, Novo Nordisk, Regeneron, Veru, Zomagen, and ZyVersa, participated on an advisory board for Epitomee, Altimmune, Novo Nordisk, Boehringer Ingelheim, and Kiniksa, and serves as Chief Science Officer and President-Elect of The Obesity Medicine Association. FLG has received grant support from Epitomee Medical Ltd, consulting fees from Altimmune, DexCom, Basic Research, and NovMeta Pharma, support for meeting attendance from BioHaven, holds patents issued or pending (US 11,534,442, US 11,058,662, US 10,897,921, US 10,507,194, US 9,999,601, US 8,334,000, US 7,709031, US 17\/245,538, and US 15\/565,367), and stock or stock options from Pep\u201419, Slim Health Nutrition, Rejuvenate Bio, Energesis, Ketogenic Health System, GATC Health, and Uplifting Results Inc. JMJ has received grant support from Epitomee Medical Ltd and the National Institutes of Health, consulting fees from Scientific Advisory Committee for Wondr Health, Inc., and holds a volunteer leadership position at the American College of Sports Medicine. HRW has received grant support from Epitomee Medical Ltd, General Mills, Novo Nordisk, Gelesis, and the National Cattleman\u2019s Beef Association, royalites or licenses from State of Slim (book), IP owned by Shakabuku, and IP licensed to University of Colorado, consulting fees from Gelesis, honoraria from the Cardio Metabolic Health Conference and the Institute for Medical and Nursing Education, holds a patient issued or pending for Energy Gap, and holds stock or stock options for Shakabuku LLC (equity ownership interest), Dr Holly LLC (equity ownership interest), and Roman Health. YK is an employee of Epitomee Medical Ltd and holds stock or stock options. Liora Cohen Asaraf is an employee of Epitomee Medical Ltd and holds stock options. DHR has received consulting fees from Altimmune, Amgen, Astra Zeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot\/Roche, CinRx, Currax, Epitomee, Fractyl, Gila, Lilly, Nestle, Novo Nordisk, Scientific Intake, Structure Therapeutics, Wondr Health, and Zealand, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk and Lilly, participated on a data safety monitoring board or advisory board for Lilly, Rhythm, and Cin Rx, and holds stock options for Epitomee, Calibrate, Roman, Scientific Intake, and Xeno.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}